Treosulfan Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Recipients

Recruiting now

Conditions studied: Pediatric Hematopoietic Stem Cell Transplantation, Malignant Disorders, Non-malignant Disorders

In brief

One of the major challenges to improve the outcome of hematopoietic stem cell transplantation (HSCT) is the reduction of toxicity and non-relapse mortality caused by the pre-transplant conditioning regimen, while maintaining efficacy. Treosulfan (TREO) (L-treitol-1,4-bis-methanesulfonate) is a busulfan analogue with a distinct site of alkylation that results in a more favourable toxicity profile in comparison with busulfan and total body irradiation. TREO is the prodrug of L-epoxybutane, a water-soluble bifunctional alkylating agent with remarkable myeloablative and immunosuppressive properties. The use of TREO, in combination with other chemotherapy agents, as part of the conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children has progressively increased during the last decade for both malignant and non-malignant disorders. Data on TREO pharmacokinetics in the pediatric population are still scarce. To date, only a few studies, including small numbers of pediatric patients, have investigated the PK profile of TREO. These studies reported high variability of TREO pharmacokinetics, and the relationship between TREO exposure, toxicity and clinical outcome is still unresolved. Therefore, therapeutic drug monitoring with a personalized approach may be an important tool to optimize outcomes in the pediatric population. The aim of the investigators' study is to characterize TREO PK/PD profiles in children undergoing HSCT and to evaluate the relationship between TREO exposure and early toxicity and clinical outcome.

Key facts

Study ID

NCT06861257

Run by

Fondazione IRCCS Policlinico San Matteo di Pavia

People needed

70

Starts

2021-02-24

Expected to finish

2027-07-31

Last updated by the study team

2026-04-24

Who can join

Age: any, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age range 0 - 18 years.
• Life expectancy > 12 weeks.
• Diagnosis of malignant or non-malignant disorder.
• Pre-HSCT Lansky / Karnofsky score ≥ 40%.
• Indication to allogeneic or autologous HSCT with TREO as part of the pre-transplant conditioning regimen.
• Negativity of pregnancy test for female patients.
• Written informed consent signed by the parents or guardians.

You may not qualify if…

• Absence of written informed consent signed by the parents or guardians.
• Current clinically active infectious disease (including positive HIV serology or viral RNA).
• Severe cardiovascular disease (arrhythmias requiring chronic treatment, congestive heart failure or left ventricular ejection fraction <40%).
• Liver dysfunction (AST/ALT ≥ 3 times institutional upper limit normal value -ULN- or bilirubin > 3 times ULN).
• Renal dysfunction: serum creatinine > 1.5 times ULN or calculated creatinine clearance < 60 ml/min/1.73 m2
• End stage irreversible multi-system organ failure.
• Pregnant or breast feeding female patient.

Where it is running

• Policlinico Sant'Orsola Malpighi, Clinica Pediatrica Oncologia Ed Ematologia Pediatrica "Lalla Seràgnoli" — Bologna, bOLOGNA, Italy (enrolling)
• Ospedali Civili, Presidio Ospedale Dei Bambini, Oncoematologia Pediatrica e TMO — Brescia, Brescia, Italy (enrolling)
• IRCCS Istituto Giannina Gaslini, U.O.S.D. Centro Trapianto di Midollo Osseo — Genova, Genova, Italy (enrolling)
• Ospedale San Raffaele, U.O. Immunoematologia Pediatrica — Milan, Milano, Italy (enrolling)
• Fondazione IRCCS San Gerardo dei Tintori - Clinica Pediatrica — Monza, Monza-brianza, Italy (enrolling)
• Azienda Ospedaliera di Padova, Oncoematologia Pediatrica — Padova, Padova, Italy (enrolling)
• Fondazione IRCCS Policlinico San Matteo, S.C. Ematologia 2 - Oncoematologia Pediatrica — Pavia, Pavia, Italy (enrolling)
• AOU Città della Salute e della Scienza Di Torino, SC Oncoematologia Pediatrica e Centro Trapianti — Torino, Torino, Italy (enrolling)
• IRCCS Materno Infantile "Burlo Garofolo", SC Oncoematologia Pediatrica e SS Trapianto Di Midollo — Trieste, Trieste, Italy (enrolling)
• Ospedale Donna Bambino Azienda Ospedaliera Universitaria Integrata, U.O.C. Oncoematologia Pediatrica — Verona, VR, Italy (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.